Policy Decision and Expert Reviews
The UK announced an indefinite ban on the sale and supply of puberty blockers to under-18s, citing advice from the (CHM) about "unacceptable safety risks".
This decision follows the and evidence reviews by and , which highlighted insufficient evidence for the safety and effectiveness of puberty blockers in treating gender dysphoria in children.
Implementation and Future Actions
Health Secretary emphasized the need for caution and evidence-led healthcare for children, announcing plans for a clinical trial in 2025 to establish a clear evidence base for puberty blockers.
The government is also working with NHS England to open new gender identity services, aiming to provide holistic health and wellbeing support for young people experiencing gender dysphoria.